Who
Timothy J. Sangiovanni
SVP, Finance & Corp Controller
Company insider
Files Form 4 as: SVP, Finance & Corp Controller, Zevra Therapeutics.
In numbers
- Trades disclosed
- 38
- Buys
- 7
- Sells
- 3
- Bought
- $18K
- Sold
- $110K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 25 Jan 2018
- Last trade
- 28 May 2026
- Last filed
- 29 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 May 2026filed 29 May 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $28K3,000 at $9.18 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $28K3,000 at $9.18 | filing |
| 31 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,666 | filing |
| 31 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,666 at $0.00 | filing |
| 31 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,666 at $0.00 | filing |
| 31 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,666 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —6,333 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $15K1,750 at $8.82 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,333 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,333 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —6,333 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $15K1,750 at $8.82 | filing |
| 13 Feb 2025filed 14 Feb 2025 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $24K3,000 at $7.86 | filing |
| 31 Jan 2025filed 3 Feb 2025 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,666 at $0.00 | filing |
| 31 Jan 2025filed 3 Feb 2025 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,666 | filing |
| 30 Jan 2025filed 3 Feb 2025 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.